Elanco Animal Health Incorporated Common Stock (ELAN)
22.25
+1.01 (4.76%)
NYSE · Last Trade: Nov 21st, 11:14 PM EST
Detailed Quote
Previous Close
21.24
Open
21.64
Bid
21.07
Ask
22.59
Day's Range
21.44 - 22.29
52 Week Range
8.020 - 23.09
Volume
8,263,464
Market Cap
11.00B
PE Ratio (TTM)
370.83
EPS (TTM)
0.1
Dividend & Yield
N/A (N/A)
1 Month Average Volume
5,813,838
Chart
About Elanco Animal Health Incorporated Common Stock (ELAN)
Elanco Animal Health Inc is a global leader in the development and manufacturing of products for animal health and well-being. The company focuses on providing innovative solutions for companion and livestock animals, which include a wide range of vaccines, pharmaceuticals, and nutritional products designed to prevent and treat diseases. By combining science and technology, Elanco aims to enhance animal care and improve food safety while promoting sustainable farming practices. With a commitment to animal health and welfare, the company partners with veterinarians, farmers, and pet owners to deliver effective health management solutions. Read More
NICE sits at the center of two critical enterprise markets: customer experience and financial crime prevention. This piece breaks down what is changing inside the business and why its next phase of cloud and AI adoption matters for investors.
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
Elanco's third quarter performance was marked by strong revenue growth across both pet and farm animal segments, with management highlighting U.S. Farm Animal up 20% and solid momentum in U.S. pet health. CEO Jeffrey Simmons attributed the results to the company’s expanding innovation portfolio, particularly new products like Credelio Quattro and Zenrelia. Despite these achievements and operational improvements, the market responded negatively, reflecting ongoing concerns about margin sustainability and competitive pressures. CFO Bob VanHimbergen noted that increased investments in global pet health launches contributed to operating expense growth, though these were partially offset by productivity gains and deleveraging efforts.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth.
This has capped returns as the industry’s six-month gain of 9.8% has lagged the S&P 500’s 17.2% climb.
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns. This divergence was stark: the tech-heavy Nasdaq struggled, losing 0.2%, while the Dow rallied.
This shift away from tech was triggered by a series of negative catalysts in the AI sector. AI cloud provider CoreWeave slid on disappointing guidance, while chip darling Nvidia pulled back after SoftBank sold its stake. This "hurt the AI trade," dragging down related names like Micron and Oracle.
As capital left tech, it sought safety in "higher quality" defensive names. Health care giants like Merck, Amgen, and Johnson & Johnson saw significant buying, boosting the Dow.
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions.
While many thrive during risk-on environments, many also struggle to maintain investor confidence when the ride gets bumpy.
Animal health company Elanco (NYSE:ELAN) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 10.4% year on year to $1.14 billion. Guidance for next quarter’s revenue was better than expected at $1.10 billion at the midpoint, 1.9% above analysts’ estimates. Its non-GAAP profit of $0.19 per share was 43.9% above analysts’ consensus estimates.
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations.
However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
Animal health company Elanco (NYSE:ELAN) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 10.4% year on year to $1.14 billion. Guidance for next quarter’s revenue was better than expected at $1.10 billion at the midpoint, 1.9% above analysts’ estimates. Its non-GAAP profit of $0.19 per share was 43.9% above analysts’ consensus estimates.
The past six months have been a windfall for Elanco’s shareholders. The company’s stock price has jumped 127%, hitting $21.47 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
The stocks featured in this article have all approached their 52-week highs.
When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
The stocks featured in this article have all approached their 52-week highs.
When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
Parsippany, N.J. – October 9, 2025 – Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today declared a quarterly dividend of $0.50 per share for the fourth quarter of 2025. This proactive announcement, made well in advance of the payment date, underscores the company's consistent commitment to shareholder
NEW YORK, NY – October 9, 2025 – Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today announced a quarterly dividend of $0.50 per share for the fourth quarter of 2025. This declaration, made on the current date of October 9, 2025, underscores the company's consistent commitment to shareholder
Shares of animal health company Elanco (NYSE:ELAN)
rose in the morning session after JP Morgan upgraded the company's stock from "Neutral" to "Overweight" and raised its price target. The analyst, Chris Schott, increased the price target from $18.00 to $24.00. The upgrade was reportedly driven by an attractive innovation cycle and successful product launches. For instance, the company's parasite protection product, Credelio Quattro, reached $100 million in net sales in under eight months. Analysts noted that Elanco's promising portfolio of new products, including future items like Zenrelia, was expected to boost growth.
The global cattle feeding industry is at a critical juncture, facing mounting pressures from volatile feed costs, stringent environmental regulations, and a persistent labor crunch. In response, a wave of innovative technologies is rapidly transforming traditional practices, promising enhanced efficiency, sustainability, and profitability. This technological pivot, driven by advancements in
